Entera Bio: Up on FDA nod for U.S. trial of osteoporosis treatment

Entera Bio

10/12/2020 17:55

** U.S.-listed shares of Israel-based drugmaker  ENTX.O 
rise 5.4% to $1.16
    ** Co says U.S. FDA has allowed it to conduct clinical trial
in the country for its osteoporosis treatment candidate, EB613
 urn:newsml:reuters.com:*:nGNXbWGFwf
    ** Mid-stage trial of EB613 in postmenopausal female
subjects with osteoporosis is currently underway in Israel 
    ** ENTX intends to report final biomarker data from the
ongoing trial in Q1 of 2021 and final bone-mineral density data
in Q2 of next year
    ** Osteoporosis is a bone disease that causes loss of bone
density, increasing risk of fractures
    ** Stock down ~46% so far this year

 (Reporting by Mrinalika Roy in Bengaluru)
 ((mrinalika.roy@thomsonreuters.com; within U.S. +1 646 223
8780, outside U.S. +91 806749 8325;))